Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SRPT with free AI briefings, catalyst countdowns, and dilution alerts.

SRPT · Sarepta Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$878.8M Cash on Hand
CF+ Cash Runway
Follow SRPT by email Get an email when SRPT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SRPT, unsubscribe in one click. Privacy

📣 What SRPT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Golodirsen
FDA approved Dec 2019 · Vyondys 53
Duchenne Muscular Dystrophy Phase 4 · NCT04708314 Terminated
Casimersen
FDA approved Feb 2021 · Amondys 45
Duchenne Muscular Dystrophy Phase 3 · NCT02500381 Completed
Eteplirsen
FDA approved Sep 2016 · Exondys 51
Muscular Dystrophy, Duchenne Phase 3 · NCT03992430 Completed
Antibiotic Duchenne Muscular Dystrophy Phase 4 · NCT07542314 Recruiting
Glucocorticoids Duchenne Muscular Dystrophy Phase 4 · NCT07542314 Recruiting
Delandistrogene Moxeparvovec-Rokl Duchenne Muscular Dystrophy Phase 4 · NCT07542314 Recruiting
Bidridistrogene Xeboparvovec Limb-girdle Muscular Dystrophy Phase 3 · NCT06246513 Active not recruiting
Glucocorticoid Limb-girdle Muscular Dystrophy Phase 3 · NCT06246513 Active not recruiting
Corticosteroid Muscular Dystrophies, Limb-Girdle Phase 3 · NCT06952686 Withdrawn
SRP-9005 Muscular Dystrophies, Limb-Girdle Phase 3 · NCT06952686 Withdrawn
AVI-4658 (Eteplirsen) Duchenne Muscular Dystrophy Phase 1/2 · NCT00159250 Completed
SRP-1001 for Injection Muscular Dystrophy, Facioscapulohumeral Phase 1/2 · NCT06131983 Enrolling by invitation
SRP-1003 IV Infusion Myotonic Dystrophy 1 Phase 1/2 · NCT06138743 Enrolling by invitation
SRP-1003 SC Injection Myotonic Dystrophy 1 Phase 1/2 · NCT06138743 Enrolling by invitation
Vesleteplirsen Muscular Dystrophy, Duchenne Phase 1/2 · NCT03675126 Terminated
rAAVrh74.MHCK7.DYSF.DV Dysferlinopathy Phase 1 · NCT02710500 Completed

Also used in these trials (approved or third-party drugs, not SRPT's own candidates): Sirolimus.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SRPT holds $878.8M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SRPT files for a raise →

👥 Who Owns SRPT

Insiders 6% Institutions (436 holders) 94% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 16,642,620 15.52% 2026-06-30
Vanguard Portfolio Management Institution (13G, 5%+) 8,499,421 7.93% 2026-06-30
STATE STREET CORPORATION Institution (13G, 5%+) 7,412,275 6.91% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 5,369,116 5.01% 2026-03-31
Richard Barry
Director
Insider 3,233,542 3.02% 2026-06-04
Douglas S Ingram
Chief Executive Officer, Director
Insider 929,391 0.87% 2025-12-07
Michael Severino
Chief Executive Officer, Director · +2.22M options
Insider 756,104 0.71% 2026-07-28
Michael Andrew Chambers
Director
Insider 504,027 0.47% 2026-06-04
M Kathleen Behrens
Director
Insider 224,357 0.21% 2026-06-04
Louise Rodino-Klapac
President, R&D and Tech Ops
Insider 203,900 0.19% 2026-09-04
Ian Michael Estepan
Chief Operating Officer
Insider 177,184 0.17% 2026-09-04
Ryan Ho-Yan Wong
Chief Financial Officer
Insider 121,792 0.11% 2026-09-04

Share count 107,235,848 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SRPT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SRPT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.